NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET
NLS 將於美國東部時間 2023 年 7 月 6 日星期四上午 11:00 對其活動進行網絡直播
ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update. The webcast will now take place on Thursday, July 6, 2023, at 11:00AM ET. Members of the NLS Leadership Team will discuss the global strategic research and development progress and platform, including:
瑞士蘇黎世/ACCESSWIRE /2023 年 6 月 30 日/ NLS Pharmaceutics Ltd.（納斯達克股票代碼：NLSP）（納斯達克股票代碼：NLSP）（納斯達克股票代碼：NLSPW）（“NLS” 或 “公司”）是一家瑞士臨床階段的生物製藥公司，專注於爲罕見和複雜的中樞神經系統疾病患者發現和開發創新療法，該公司今天宣佈，由於重要進展影響了公司更新的時機，它將推遲原定於今天舉行的網絡直播。網絡直播現在將在美國東部時間2023年7月6日星期四上午11點舉行。NLS領導團隊的成員將討論全球戰略研發進展和平臺，包括：
- Feedback from the SLEEP 2023 APSS Conference
- Initiation of the Phase 3 program AMAZE for Mazindol ER
- Pipeline Goals for 2023/2024
- Key Financials
- Funding Strategy Update
- Corporate Development
- 來自 SLEEP 2023 APSS 會議的反饋
- 爲 Mazindol ER 啓動第 3 階段計劃 AMAZE
- 2023/2024 年計劃目標
- 主要財務狀況
- 融資策略更新
- 企業發展
Webcast Information
網絡直播信息
The event will be held July 6, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website found here or at the SummitCast event page found here. A replay will be available on NLS' website within 48 hours after the event.
該活動將於美國東部時間2023年7月6日上午11點舉行，並將包括公司網站投資者部分的視頻直播，也可以在這裏找到的SummitCast活動頁面。活動結束後48小時內將在NLS的網站上提供重播。
About NLS Pharmaceutics Ltd.
關於 NLS 製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（納斯達克股票代碼：NLSP）是一家處於開發階段的全球生物製藥公司，與世界一流的合作伙伴和國際知名的科學家網絡合作，專注於爲醫療需求未得到滿足的罕見和複雜中樞神經系統疾病患者發現和開發創新療法。NLS總部位於瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，他們在開發和商業化候選產品方面有着良好的記錄。欲瞭解更多信息，請訪問。
For additional information:
欲瞭解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
瑪麗安·蘭伯森（投資者和媒體）
NLS 製藥有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
來源： NLS 製藥股份有限公司